NDA submitted for glycopyrrolate oral solution for pediatric drooling

Sciele Pharma announced that it has submitted a New Drug Application (NDA) to the FDA for glycopyrrolate oral solution to treat chronic, moderate-to-severe drooling in pediatric patients. This condition often results from cerebral palsy as well as from other neurological disorders. Glycopyrrolate oral solution has received orphan drug designation from the FDA.

For more information call (800) 461-3696 or visit www.sciele.com.